KAT6A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL418502	0.53	19/20
SCHEMBL660454	0.51	13/20
SCHEMBL873113	0.45	10/20
SCHEMBL660141	0.51	9/20
SCHEMBL196140	0.72	8/20
SCHEMBL156679	0.59	8/20
SCHEMBL382665	0.48	8/20
SCHEMBL1028459	0.53	7/20
SCHEMBL420408	0.50	6/20
SCHEMBL419115	0.44	6/20
SCHEMBL310089	0.44	6/20
SCHEMBL384443	0.42	6/20
SCHEMBL545473	0.42	6/20
SCHEMBL365236	0.53	5/20
SCHEMBL394835	0.46	5/20
SCHEMBL979817	0.43	5/20
SCHEMBL446533	0.35	5/20
SCHEMBL667703	0.60	4/20
SCHEMBL679553	0.58	4/20
SCHEMBL690501	0.54	4/20

Clinical trials — most relevant to KAT6A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Symbicort ® on GR in Sputum in COPD	PHASE4	COMPLETED
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer	PHASE2	UNKNOWN
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS	PHASE2	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia	nan	RECRUITING
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Assessment of Memory in Children With Kabuki Syndrom	nan	COMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Impact of Metabolic Health on Sperm Epigenetic Marks in Humans	nan	ACTIVE_NOT_RECRUITING
DNA Methylation and Autoimmune Thyroid Diseases	nan	COMPLETED
Israeli Multi Ethnic Centenarian Project	nan	COMPLETED
Precision High-Intensity Training Through Epigenetics (PHITE)	nan	COMPLETED
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
Family Resilience Initiative Research Program	nan	UNKNOWN
Familial Investigations of Childhood Cancer Predisposition	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a KAT6A binder may also engage these)

Protein	Name	Similarity
Q5TKR9	—	1.000	Q5TKR9 →
Q8WML3	—	1.000	Q8WML3 →
Q8BZ21	—	1.000	Q8BZ21 →
KAT6B	Histone acetyltransferase KAT6B	0.997	landscape →
Q8BMD7	—	0.997	Q8BMD7 →
A6QP06	—	0.995	A6QP06 →
BPTF	Nucleosome-remodeling factor subunit BPTF	0.994	landscape →
Q99PI5	—	0.994	Q99PI5 →
Q8BRB7	—	0.993	Q8BRB7 →
O95625	—	0.993	O95625 →
Q2PFD7	—	0.993	Q2PFD7 →
Q24K09	—	0.993	Q24K09 →
Q8C0P7	—	0.993	Q8C0P7 →
Q8TDB6	—	0.993	Q8TDB6 →
Q5SVQ0	—	0.993	Q5SVQ0 →
Q5HZN1	—	0.993	Q5HZN1 →
Q8N3Z6	—	0.992	Q8N3Z6 →
Q9CSP9	—	0.992	Q9CSP9 →
BRPF3	Bromodomain and PHD finger-containing protein 3	0.992	landscape →
Q8K3E5	—	0.992	Q8K3E5 →
E1C2V1	—	0.992	E1C2V1 →
Q92539	—	0.992	Q92539 →
P10244	—	0.992	P10244 →
KAT7	Histone acetyltransferase KAT7	0.992	landscape →
Q6IVY4	—	0.992	Q6IVY4 →
Q92613	—	0.992	Q92613 →
Q8VCD7	—	0.992	Q8VCD7 →
Q9Z2U2	—	0.991	Q9Z2U2 →
Q08BS4	—	0.991	Q08BS4 →
Q8NEM8	—	0.991	Q8NEM8 →